Nama's AI scorecard currently rates Edwards Lifesciences Buy (7.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is EW's P/E ratio?

Edwards Lifesciences trades at a trailing price-to-earnings ratio of 34.7.

When does EW report earnings?

Edwards Lifesciences's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $0.71.

What is the EW price target?

The median analyst price target from 27 analysts is $103.00, with a range of $84.00 – $117.00.

Is EW Shariah compliant?

Nama's AAOIFI-style screen reads Edwards Lifesciences as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Edwards Lifesciences (EW)

Healthcare · Medical Devices · NYSE

S&P 500

Edwards Lifesciences (EW) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $58.73B, a trailing price-to-earnings ratio of 34.7 and a free-cash-flow yield of 2.2%. Over the most recent reported fiscal year, revenue grew 11.6% and free cash flow per share grew 425.5%. Nama's AI scorecard rates it Buy, 7.7 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 7.7/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Middle · +4.1% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-22.5%

How far the last close sits under the highest price of the past five years.

Market cap	$58.73B
Trailing P/E	34.7
Price / book	5.5
Price / sales	9.0
FCF yield	2.2%
Dividend yield	—
Gross margin	77.8%
Operating margin	28.1%
Net margin	15.4%
Revenue growth (YoY)	+11.6%
Revenue growth (3-yr annual)	+10.8%
EPS growth (YoY)	-2.3%
FCF/share growth (YoY)	+425.5%
Beta	0.9
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

EW earnings

Next report: Feb 9, 2027 (Q4 2026, EPS estimate $0.71). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.80	$0.74	+8.1%	$1.72B
Q2 2026	Jul 23, 2026	$0.78	$0.74	+5.4%	$1.74B
Q1 2026	Apr 23, 2026	$0.78	$0.73	+6.8%	$1.65B
Q4 2025	Feb 10, 2026	$0.58	$0.62	-6.5%	$1.57B

EW analyst price target

Median target $103.00 from 27 analysts, ranging $84.00 – $117.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7
STE	STERIS	$24.60B	23.2

Explore live EW data on Nama Insights →

Recent Congressional trades

Edwards Lifesciences trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Josh Gottheimer	House	Sell	$1,001 - $15,000	Dec 29, 2025
Jefferson Shreve	House	Sell	$50,001 - $100,000	Jun 22, 2025
Bruce Westerman	House	Sell	$1,001 - $15,000	May 12, 2025
Rob Bresnahan	House	Buy	$1,001 - $15,000	May 8, 2025
Jefferson Shreve	House	Buy	$15,001 - $50,000	May 8, 2025
Bruce Westerman	House	Buy	$1,001 - $15,000	Apr 16, 2025
Mike Kelly	House	Sell	$1,001 - $15,000	Jun 14, 2024
Josh Gottheimer	House	Buy	$1,001 - $15,000	Jan 7, 2024
John Curtis	House	Sell	$1,001 - $15,000	Dec 15, 2023

EW FAQ

Is EW a buy?: Nama's AI scorecard currently rates Edwards Lifesciences Buy (7.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is EW's P/E ratio?: Edwards Lifesciences trades at a trailing price-to-earnings ratio of 34.7.
When does EW report earnings?: Edwards Lifesciences's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $0.71.
What is the EW price target?: The median analyst price target from 27 analysts is $103.00, with a range of $84.00 – $117.00.
Is EW Shariah compliant?: Nama's AAOIFI-style screen reads Edwards Lifesciences as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.